Journal
EXPERT OPINION ON DRUG SAFETY
Volume 21, Issue 12, Pages 1441-1443Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/14740338.2022.2160445
Keywords
romosozumab; osteoporosis; cardiovascular disease